Turkiye Klinikleri Journal of Veterinary Sciences

.: REVIEW
Kedi ve Köpeklerde Antitrombotik İlaçların Kullanımı
Use of Antithrombotic Drugs in Cats and Dogs
Zeynep ÖZDEMİR KÜTAHYAa, Bünyamin TRAŞb
aAnadolu İlaç ve Kimya Sanayi Anonim Şirketi,
bFarmakoloji ve Toksikoloji ABD, Selçuk Üniversitesi Veteriner Fakültesi, Konya, TÜRKİYE
Turkiye Klinikleri J Vet Sci. 2019;10(2):84-96
doi: 10.5336/vetsci.2019-70939
Article Language: TR
Full Text
ÖZET
 Tromboembolik hastalıklar, hayvanlarda ve özellikle kedi ve köpeklerde hayati risk oluşturan patolojik bozukluklardır. Antitrombotik ilaçlar, trombozun oluşumu ve genişlemesini önlemek için kullanılırken, trombolitik (fibrinolitik) ilaçlar oluşan pıhtıyı eritmek için kullanılır. Tromboz riskli kedi ve köpeklerde hangi grup antitrombotik ilacın ve uygulanacak dozaj rejiminin belirlenmesi klinik açıdan önem taşımaktadır. Antiplatelet ilaçlardan aspirin, klopidogrel, tiklopidin, antikoagülan ilaçlardan varfarin, heparin, düşük molekül ağırlıklı heparinler ve rivaroksaban ile fibrinolitik ilaçlardan streptokinaz kedi ve köpeklerde en sık kullanılan antitrombotik ilaçlardır. Arteriyel tromboembolizm tedavisinde antiplateletler önerilirken, venöz tromboembolizm vakalarında antikoagülanlar önerilmektedir. Bazı arteriyel tromboembolizm vakalarında ise antiplatelet ve antikoagülan ilaçlarla kombine tedavi tercih edilmektedir. Ayrıca, antitrombotik tedavinin izlenmesi, ilacın klinik etkinliğini ve istenmeyen etkilerini belirlemek için çok önemlidir. Terapötik ilaç takibi, özellikle antikoagülan ilaçlardan varfarin ve heparin gibi ilaçlar için kullanılmaktadır. Bu çalışmada, antitrombotik ilaçların kedi ve köpeklerde kullanımı, bu alandaki mevcut bilgi ve çalışmalar ışığında değerlendirilmiştir. Kedi ve köpeklerde çeşitli patofizyolojik olguların tetiklediği ve ciddi sağlık problemlerine yol açabilen trombozun önlenmesinde kullanılan antitrombotik ilaçların etkin ve güvenli kullanımı için ilave çalışmalara ihtiyaç olduğu anlaşılmaktadır.

Anahtar Kelimeler: Tromboz; kedi; köpek; antitrombotik ilaçlar
ABSTRACT
 Thromboembolic diseases are pathological disorders that are life-threatening in animals, especially in cats and dogs. Antithrombotic drugs are used to prevent the formation and extend of thrombosis, while thrombolytic (fibrinolytic) drugs are used to dissolve the clot. It is clinically important to determine group of antithrombotic drugs and dosing regimens to be administered in cats and dogs with thrombosis risk. Among the antiplatelet drugs aspirin, clopidogrel, ticlopidine, among the anticoagulant drugs warfarin, heparin and low molecular weight heparins, rivaroxaban and from the fibrinolytic drugs streptokinase is the most commonly used antithrombotic drug in cats and dogs. Antiplatelet agents are recommended for the treatment of arterial thromboembolism, while anticoagulants are recommended in cases of venous thromboembolism. In some cases of arterial thromboembolism, combined therapy with antiplatelet and anticoagulant drugs is preferred. Also monitoring antithrombotic therapy is very important to determine the clinical efficiency and adverse effects of the drug. Therapeutic drug monitoring is especially used for anticoagulant drugs such as warfarin and heparin. In this review, the usage of antithrombotic drugs in cats and dogs has been evaluated in the light of current knowledge and studies in this field. It is understood that various studies are needed for the effective and safe use of antithrombotic drugs used in the prevention of thrombosis, which can be triggered by various pathophysiological phenomena in cats and dogs and may cause serious health problems.

Keywords: Thrombosis; cat; dog; antithrombotic drugs
REFERENCES:
  1. Panek CM, Nakamura RK, Bianco D. Use of enoxaparin in dogs with primary immune-mediated hemolytic anemia: 21 cases. J Vet Emerg Crit Care (San Antonio). 2015;25(2):273-7. [Crossref]  [PubMed] 
  2. Goggs R, Blais MC, Brainard BM, Chan DL, deLaforcade AM, Rozanski E, et al. American College of Veterinary Emergency and Critical Care (ACVECC) Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE) guidelines: Small animal. J Vet Emerg Crit Care (San Antonio). 2019;29(1):12-36. [Crossref]  [PubMed] 
  3. Smith SA, Tobias AH, Jacob KA, Fine DM, Grumbles PL. Arterial thromboembolism in cats: acute crisis in 127 cases (1992-2001) and long-term management with low-dose aspirin in 24 cases. J Vet Intern Med. 2003;17(1):73-83. [Crossref]  [PubMed] 
  4. Maden M, Yildiz R, Col R, Arican M, Ider M, Garip M, et al. The evaluation of hemostatic dysfunction and disseminated intravascular coagulation in dairy cows with abomasal displacement. Pol J Vet Sci. 2018;21(4):769-78.
  5. Uney K, Tras B, Corum O, Yildiz R, Maden M. Pharmacokinetics of pentoxifylline and its 5-hydroxyhexyl metabolite following intravenous administration in cattle. Trop Anim Health Prod. 2019;51(2):435-41. [Crossref]  [PubMed] 
  6. Weinkle TK, Center SA, Randolph JF, Warner KL, Barr SC, Erb HN. Evaluation of prognostic factors, survival rates, and treatment protocols for immune-mediated hemolytic anemia in dogs: 151 cases (1993-2002). J Am Vet Med Assoc. 2005;226(11):1869-80. [Crossref]  [PubMed] 
  7. Blais MC, Bianco D, Goggs R, Lynch AM, Palmer L, Ralph A, et al. Consensus on the rational use of antithrombotics in veterinary critical care (CURATIVE): domain 3-defining antithrombotic protocols. J Vet Emerg Crit Care (San Antonio). 2019;29(1):60-74. [Crossref]  [PubMed] 
  8. Escudero M, Alvarez L, de Haro J, Millan I, Jorge E, Castillo-Olivares J. Prevention of thrombus formation on biomaterials exposed to blood using different antiplatelet drugs: experimental study in dogs. J Biomed Mater Res. 1994;28(1):1-6. [Crossref]  [PubMed] 
  9. Hernandez-Maldonado JJ, Padberg FT Jr, Teehan E, Neville R, DeFouw D, Duran WN, et al. Arterial intimal flaps: a comparison of primary repair, aspirin, and endovascular excision in an experimental model. J Trauma. 1993;34(4):565-9. [Crossref] 
  10. Yao SK, Benedict CR, Rosolowsky M, McNatt J, Falinska B, Campbell WB, et al. Effect of aspirin on local prostaglandin production and serotonin accumulation in a canine model with coronary cyclic flow variations or thrombosis. J Mol Cell Cardiol. 1991;23(4):473-82.
  11. Mickelson JK, Hoff PT, Homeister JW, Fantone JC, Lucchesi BR. High dose intravenous aspirin, not low dose intravenous or oral aspirin, inhibits thrombus formation and stabilizes blood flow in experimental coronary vascular injury. J Am Coll Cardiol. 1993;21(2):502-10. [Crossref] 
  12. Roux SP, Tschopp TB, Kuhn H, Steiner B, Hadvary P. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog. J Pharmacol Exp Ther. 1993;264(1):501-8.
  13. Bech FR, Cronenwett JL, McDaniel MD, Ogletree ML, Freeman DH Jr. The effect of thromboxane receptor blockade versus thromboxane synthase inhibition on canine arterial graft patency. J Vasc Surg. 1990;12(2):119-25. [Crossref] 
  14. McDaniel MD, Huntsman WT, Miett TO, Cronenwett JL. Effect of a selective thromboxane synthase inhibitor on arterial graft patency and platelet deposition in dogs. Arch Surg. 1987;122(8):887-92. [Crossref]  [PubMed] 
  15. Mellett AM, Nakamura RK, Bianco D. A prospective study of clopidogrel therapy in dogs with primary immune-mediated hemolytic anemia. J Vet Intern Med. 2011;25(1):71-5. [Crossref]  [PubMed] 
  16. Shaw N, Burrows CF, King RR. Massive gastric hemorrhage induced by buffered aspirin in a greyhound. J Am Anim Hosp Assoc. 1997;33(3):215-9. [Crossref]  [PubMed] 
  17. Rawlings CA, Keith JC, Lewis RE, Losonsky JM, McCall JW. Aspirin and prednisolone modification of radiographic changes caused by adulticide treatment in dogs with heartworm infection. J Am Vet Med Assoc. 1983;182(2):131-6.
  18. Boudreaux MK, Dillon AR, Ravis WR, Sartin EA, Spano JS. Effects of treatment with aspirin or aspirin/dipyridamole combination in heartworm-negative, heartworm-infected, and embolized heartworm-infected dogs. Am J Vet Res. 1991;52(12):1992-9.
  19. Schaub RG, Keith JC Jr, Rawlings CA. Effect of acetylsalicylic acid on vascular damage and myointimal proliferation in canine pulmonary arteries subjected to chronic injury by Dirofilaria immitis. Am J Vet Res. 1983;44(3):449-54.
  20. Schaub RG, Rawlings CA, Keith JC Jr. Effect of long-term aspirin treatment on platelet adhesion to chronically damaged canine pulmonary arteries. Thromb Haemost. 1981;46(4):680-3. [Crossref]  [PubMed] 
  21. Hogan DF, Fox PR, Jacob K, Keene B, Laste NJ, Rosenthal S, et al. Secondary prevention of cardiogenic arterial thromboembolism in the cat: the double-blind, randomized, positive-controlled feline arterial thromboembolism; clopidogrel vs. aspirin trial (FAT CAT). J Vet Cardiol. 2015;17 Suppl 1:S306-17. [Crossref]  [PubMed] 
  22. Schoeman JP. Feline distal aortic thromboembolism: a review of 44 cases (1990-1998). J Feline Med Surg. 1999;1(4):221-31. [Crossref]  [PubMed] 
  23. Rawlings CA. Pulmonary arteriography and hemodynamics during feline heartworm disease. Effect of aspirin. J Vet Intern Med. 1990;4(6):285-91. [Crossref]  [PubMed] 
  24. De Clerck F, Loots W, Somers Y, Beetens J, Wouters L, Wynants J, et al. 5-hydroxytryptamine and arachidonic acid metabolites modulate extensive platelet activation induced by collagen in cats in vivo. Br J Pharmacol. 1990;99(4):631-6. [Crossref]  [PubMed]  [PMC] 
  25. Behrend EN, Grauer GF, Greco DS, Rose BJ, Thrall M. Comparison of the effects of diltiazem and aspirin on platelet aggregation in cats. J Am Anim Hosp Assoc. 1996;32(1):11-8. [Crossref]  [PubMed] 
  26. Davidson BC, Haggan J. Dietary polyenoic fatty acids change the response of cat blood platelets to inductions of aggregation by ADP. Prostaglandins Leukot Essent Fatty Acids. 1990;39(1):31-7. [Crossref] 
  27. Cathcart CJ, Brainard BM, Reynolds LR, Al-Nadaf S, Budsberg SC. Lack of inhibitory effect of acetylsalicylic acid and meloxicam on whole blood platelet aggregation in cats. J Vet Emerg Crit Care (San Antonio). 2012;22(1):99-106.
  28. Ho KK, Abrams-Ogg AC, Wood RD, O'Sullivan ML, Kirby GM, Blois SL. Assessment of platelet function in healthy cats in response to commonly prescribed antiplatelet drugs using three point-of-care platelet function tests. J Feline Med Surg. 2017;19(6):638-47. [Crossref]  [PubMed] 
  29. Parton K, Balmer TV, Boyle J, Whittem T, MacHon R. The pharmacokinetics and effects of intravenously administered carprofen and salicylate on gastrointestinal mucosa and selected biochemical measurements in healthy cats. J Vet Pharmacol Ther. 2000;23(2):73-9. [Crossref]  [PubMed] 
  30. Satoh H, Amagase K, Takeuchi K. The role of food for the formation and prevention of gastrointestinal lesions induced by aspirin in cats. Dig Dis Sci. 2013;58(10):2840-9. [Crossref]  [PubMed] 
  31. Wang K, Zhou X, Huang Y, Khalil M, Wiktor D, van Giezen JJ, et al. Adjunctive treatment with ticagrelor, but not clopidogrel, added to tPA enables sustained coronary artery recanalisation with recovery of myocardium perfusion in a canine coronary thrombosis model. Thromb Haemost. 2010;104(09):609-17. [Crossref]  [PubMed] 
  32. Wang YX, Vincelette J, da Cunha V, Martin-McNulty B, Mallari C, Fitch RM, et al. A novel P2Y(12) adenosine diphosphate receptor antagonist that inhibits platelet aggregation and thrombus formation in rat and dog models. Thromb Haemost. 2007;97(5):847-55. [Crossref]  [PubMed] 
  33. Borgarelli M, Lanz O, Pavlisko N, Abbott JA, Menciotti G, Aherne M, et al. Mitral valve repair in dogs using an ePTFE chordal implantation device: a pilot study. J Vet Cardiol. 2017;19(3):256-67. [Crossref]  [PubMed] 
  34. Brainard BM, Kleine SA, Papich MG, Budsberg SC. Pharmacodynamic and pharmacokinetic evaluation of clopidogrel and the carboxylic acid metabolite SR 26334 in healthy dogs. Am J Vet Res. 2010;71(7):822-30. [Crossref]  [PubMed] 
  35. Bjorkman JA, Zachrisson H, Forsberg GB, von Bahr H, Hansson GI, Warner TD, et al. High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition. Thromb Res. 2013;131(4):313-9. [Crossref]  [PubMed] 
  36. Hagihara K, Kazui M, Ikenaga H, Nanba T, Fusegawa K, Takahashi M, et al. Comparison of formation of thiolactones and active metabolites of prasugrel and clopidogrel in rats and dogs. Xenobiotica. 2009;39(3):218-26. [Crossref]  [PubMed] 
  37. Hogan DF, Andrews DA, Green HW, Talbott KK, Ward MP, Calloway BM. Antiplatelet effects and pharmacodynamics of clopidogrel in cats. J Am Vet Med Assoc. 2004;225(9):1406-11. [Crossref]  [PubMed] 
  38. Teuber M, Mischke R. Influence of a low dosage of clopidogrel on platelet function in cats as measured by the platelet function analyser PFA-100 and the multiplate analyser. Res Vet Sci. 2016;109:149-56. [Crossref]  [PubMed] 
  39. Riviere JE, Papich MG. Drugs acting on blood and blood elements. Veterinary Pharmacology & Therapeutics. 9th ed. USA: Wiley-Blackwell; 2009. p.688.
  40. Kaya S, Pirincci I, Unsal A, Tras B, Bilgili A, Akar F. [Drugs that cause and relieve bleeding]. Kaya S, editor. Veteriner Farmakoloji. 1. Cilt. 5. Baski. Ankara: Medisan; 2009. p.482-5.
  41. Kayaalp SO, Akici A, Akova M, Kaleli Duman M, Erdemli I, Babaooglu MO, et al. [Antithrombotic drugs: anticoagulant drugs, antithrombocytic drugs and thrombolytic drugs]. Kayaalp SO, editor. Akilci Tedavi Yonunden Tibbi Farmakoloji. 1. Cilt. 13. Baski. Ankara: Pelikan Yayincilik Ltd. Sti; 2012. p.517, 531-32.
  42. Shen C, Huang X, Li J, Zhang P, Li L, Zhang W, et al. Pharmacokinetic and pharmacodynamic interactions of aspirin with warfarin in beagle dogs. Xenobiotica. 2016;46(6):530-41. [Crossref]  [PubMed] 
  43. Monnet E, Morgan MR. Effect of three loading doses of warfarin on the international normalized ratio for dogs. Am J Vet Res. 2000;61(1):48-50. [Crossref]  [PubMed] 
  44. Makutani S, Kichikawa K, Uchida H, Maeda M, Konishi N, Hiasa Y, et al. Effect of antithrombotic agents on the patency of PTFE-covered stents in the inferior vena cava: an experimental study. Cardiovasc Intervent Radiol. 1999;22(3):232-8. [Crossref]  [PubMed] 
  45. Hoffman MJ, Stewart JR, Greenfield LJ. Effects of coumadin on the resolution of canine venous thrombi. J Surg Res. 1986;40(1):1-5. [Crossref] 
  46. Hoak JC, Connor WE, Warner ED. The antithrombotic effects of sodium heparin and sodium warfarin. Arch Intern Med. 1966;117(1):25-31. [Crossref]  [PubMed] 
  47. Lantz GC, Badylak SF, Coffey AC, Geddes LA, Sandusky GE. Small intestinal submucosa as a superior vena cava graft in the dog. J Surg Res. 1992;53(2):175-81. [Crossref] 
  48. Winter RL, Sedacca CD, Adams A, Orton EC. Aortic thrombosis in dogs: presentation, therapy, and outcome in 26 cases. J Vet Cardiol. 2012;14(2):333-42. [Crossref]  [PubMed] 
  49. Arai S, Griffiths LG, Mama K, Hackett TB, Monnet E, Boon JA, et al. Bioprosthesis valve replacement in dogs with congenital tricuspid valve dysplasia: technique and outcome. J Vet Cardiol. 2011;13(2):91-9. [Crossref]  [PubMed] 
  50. Arai S, Callan MB. Warfarin therapy in a dog with acute arterial thrombosis and pyometra. Can Vet J. 2014;55(11):1066-8.
  51. Choppin A, Irwin I, Lach L, McDonald MG, Rettie AE, Shao L, et al. Effect of tecarfarin, a novel vitamin K epoxide reductase inhibitor, on coagulation in beagle dogs. Br J Pharmacol. 2009;158(6):1536-47. [Crossref]  [PubMed]  [PMC] 
  52. Todd RS, Sive EB, DeJode LR, Danese C, Howard JM. Replacement of segments of the venous system. Arch Surg. 1963;87(6):998-1002. [Crossref]  [PubMed] 
  53. Dale J, Aasen AO, Resch F, Semb B, Stadskleiv K, Lilleaasen P. Mitral disc valve implantation in the dog: early and late valve thrombosis and its prevention. Eur Surg Res. 1983;15(5):249-55. [Crossref]  [PubMed] 
  54. Neff-Davis CA, Davis LE, Gillette EL. Warfarin in the dog: pharmacokinetics as related to clinical response. J Vet Pharmacol Ther. 1981;4(2):135-40. [Crossref]  [PubMed] 
  55. Wheat JC, Hall TL, Hempel CR, Cain CA, Xu Z, Roberts WW. Prostate histotripsy in an anticoagulated model. Urology. 2010;75(1):207-11. [Crossref]  [PubMed]  [PMC] 
  56. Pouchelon JL, Chetboul V, Devauchelle P, Delisle F, Mai W, Vial V. Diagnosis of pulmonary thromboembolism in a cat using echocardiography and pulmonary scintigraphy. J Small Anim Pract. 1997;38(7):306-10. [Crossref]  [PubMed] 
  57. Smith SA, Kraft SL, Lewis DC, Melethil S, Freeman LC. Pharmacodynamics of warfarin in cats. J Vet Pharmacol Ther. 2000;23(6):339-44. [Crossref]  [PubMed] 
  58. Piegras DG, Sundt TM Jr, Didisheim P. Effect of anticoagulants and inhibitors of platelet aggregation on thrombotic occlusion of endarterectomized cat carotid arteries. Stroke. 1976;7(3):248-54. [Crossref]  [PubMed] 
  59. Smith SA, Kraft SL, Lewis DC, Freeman LC. Plasma pharmacokinetics of warfarin enantiomers in cats. J Vet Pharmacol Ther. 2000;23(6):329-37. [Crossref]  [PubMed] 
  60. Binymin KA, Nasher M, Patel D. Warfarin-induced deep vein thrombosis. Int Med Case Rep J. 2014;7:123-5. [Crossref]  [PubMed]  [PMC] 
  61. Helmond SE, Polzin DJ, Armstrong PJ, Finke M, Smith SA. Treatment of immune-mediated hemolytic anemia with individually adjusted heparin dosing in dogs. J Vet Intern Med. 2010;24(3):597-605. [Crossref]  [PubMed] 
  62. Scott KC, Hansen BD, DeFrancesco TC. Coagulation effects of low molecular weight heparin compared with heparin in dogs considered to be at risk for clinically significant venous thrombosis. J Vet Emerg Crit Care (San Antonio). 2009;19(1):74-80. [Crossref]  [PubMed] 
  63. Erickson M, Hiebert LM, Carr AP, Stickney JD. Effect of oral administration of unfractionated heparin (UFH) on coagulation parameters in plasma and levels of urine and fecal heparin in dogs. Can J Vet Res. 2014;78(3):193-201.
  64. Manion JS, Thomason JM, Langston VC, Claude AK, Brooks MB, Mackin AJ, et al. Anticoagulant effects of inhaled unfractionated heparin in the dog as determined by partial thromboplastin time and factor Xa activity. J Vet Emerg Crit Care (San Antonio). 2016;26(1):132-6. [Crossref]  [PubMed] 
  65. Morris TA, Marsh JJ, Konopka R, Pedersen CA, Chiles PG. Anti-thrombotic efficacies of enoxaparin, dalteparin, and unfractionated heparin in venous thrombo-embolism. Thromb Res. 2000;100(3):185-94. [Crossref] 
  66. Alwood AJ, Downend AB, Brooks MB, Slensky KA, Fox JA, Simpson SA, et al. Anticoagulant effects of low-molecular-weight heparins in healthy cats. J Vet Intern Med. 2007;21(3):378-87. [Crossref]  [PubMed] 
  67. Lynch AM, deLaforcade AM, Sharp CR. Clinical experience of anti-Xa monitoring in critically ill dogs receiving dalteparin. J Vet Emerg Crit Care (San Antonio). 2014;24(4):421-8. [Crossref]  [PubMed] 
  68. Schonig JC, Mischke RH. Assessment of the effects of dalteparin on coagulation variables and determination of a treatment schedule for use in cats. Am J Vet Res. 2016;77(7):700-7. [Crossref]  [PubMed] 
  69. Rhue KE, Taylor AR, Cole RC, Winter RL. Bilateral vertebral venous sinus thrombosis causing cervical spinal cord compression in a dog. Front Vet Sci. 2017;4:8. [Crossref]  [PubMed]  [PMC] 
  70. Pouzot-Nevoret C, Barthelemy A, Cluzel M, Verwaerde P, Bonnet-Garin JM, Goy-Thollot I. Enoxaparin has no significant anticoagulation activity in healthy Beagles at a dose of 0.8 mg/kg four times daily. Vet J. 2016;210:98-100. [Crossref]  [PubMed] 
  71. Van De Wiele C, Hogan DF, Green HW 3rd, Sederquist KD. Antithrombotic effect of enoxaparin in clinically healthy cats: a venous stasis model. J Vet Intern Med. 2010;24(1):185-91. [Crossref]  [PubMed] 
  72. Mischke R, Schonig J, Doderlein E, Wolken S, Bohm C, Kietzmann M. Enoxaparin: pharmacokinetics and treatment schedule for cats. Vet J. 2014;200(3):375-81. [Crossref]  [PubMed] 
  73. Fiakpui NN, Hogan DF, Whittem T, Green HW 3rd, Shipley EA, Sederquist KA. Dose determination of fondaparinux in healthy cats. Am J Vet Res. 2012;73(4):556-61. [Crossref]  [PubMed] 
  74. Morassi A, Bianco D, Park E, Nakamura RK, White GA. Evaluation of the safety and tolerability of rivaroxaban in dogs with presumed primary immune-mediated hemolytic anemia. J Vet Emerg Crit Care (San Antonio). 2016;26(4):488-94. [Crossref]  [PubMed] 
  75. Conversy B, Blais MC, Dunn M, Gara-Boivin C, Del Castillo JE. Anticoagulant activity of oral rivaroxaban in healthy dogs. Vet J. 2017;223:5-11. [Crossref]  [PubMed] 
  76. Yang VK, Cunningham SM, Rush JE, de Laforcade A. The use of rivaroxaban for the treatment of thrombotic complications in four dogs. J Vet Emerg Crit Care (San Antonio). 2016;26(5):729-36. [Crossref]  [PubMed] 
  77. Dixon-Jimenez AC, Brainard BM, Brooks MB, Nie B, Arnold RD, Loper D, et al. Pharmacokinetic and pharmacodynamic evaluation of oral rivaroxaban in healthy adult cats. J Vet Emerg Crit Care (San Antonio). 2016;26(5):619-29. [Crossref]  [PubMed] 
  78. Boothe DM. Therapeutic drug monitoring. Small Animal Clinical Pharmacology and Therapeutics. 2nd ed. Philadelphia, PA: WB Saunders; 2012. p.112-27.
  79. Sharp CR, deLaforcade AM, Koenigshof AM, Lynch AM, Thomason JM. Consensus on the Rational Use of Antithrombotics in Veterinary Critical Care (CURATIVE): Domain 4-Refining and monitoring antithrombotic therapies. J Vet Emerg Crit Care (San Antonio). 2019;29(1):75-87. [Crossref]  [PubMed] 
  80. Lantz GC, Badylak SF, Coffey AC, Geddes LA, Blevins WE. Small intestinal submucosa as a small-diameter arterial graft in the dog. J Invest Surg. 1990;3(3):217-27. [Crossref]  [PubMed] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com